CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use (CHMP) recommended Xofigo® (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases. The decision of the European Commission on the approval is expected in the second half of 2013. Xofigo was approved by the U.S. Food and Drug Administration in May for the treatment of patients with CRPC, symptomatic bone metastases and no known visceral metastatic disease and is now available in the United States at licensed facilities.

"We are encouraged by the positive CHMP opinion issued today, and look forward to potentially providing radium 223 to more patients upon approval of the European Commission," explained Kemal Malik, MD, Member of the Bayer HealthCare Executive Committee and Head of Global Development.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Innovate UK funding to support the development of powdered gene therapy for bone graft augmentation